-
Mashup Score: 1Blood | American Society of Hematology - 1 year(s) ago
Skip Nav Destination Current Issue Volume 141, Issue 15, April 13 2023 …
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 1Daratumumab as a novel treatment option in refractory ITP - 1 year(s) ago
Primary immune thrombocytopenia (ITP) in adult patients typically presents as a repeatedly relapsing disease in need of multiple lines of therapy. Her…
Source: www.sciencedirect.comCategories: Hem/Oncs, Latest HeadlinesTweet-
From its off label use in the treatment of relapsed refractory T - ALL, B-ALL , post HSCT PRCA , Daratumumab , an anti CD 38 antibody FDA approved for treatment of #myeloma ,also sneaks into the therapy of refractory ITP #MedTwitter #daratumumab #mmsm https://t.co/zyX2oib3Wg
-
-
Mashup Score: 1How I prevent and treat central nervous system disease in adults with acute lymphoblastic leukemia - 1 year(s) ago
Systemic treatment of adult patients with acute lymphoblastic leukemia continues to evolve with the introduction of targeted and T-cell activating therapies, bu
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
⚡️5-11% patients with B-ALL have CNS disease @ diagnosis ⚡️with current strategies 4-15% CNS relapses 👉How to prevent and treat CNS diseases in B-ALL #ALL #leusm #hemeonc #MedTwitter . https://t.co/D4pq2l7Meh Wishing we have access to the newer therapies for all our patients https://t.co/iqvavS1GiT
-
-
Mashup Score: 0Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN - 1 year(s) ago
In this article, Döhner and international colleagues provide a major update to the European Leukemia Network (ELN) recommendations, a key guideline for physicia
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
Hierarchical classification of the International Consensus Classification of AML. #aml #leusm #medtwitter #hemeonc https://t.co/5agYdWCFiQ @BloodJournal https://t.co/NWSUdCHcRl
-
-
Mashup Score: 0Paper: Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia - 1 year(s) ago
Oral and Poster Abstracts Oral 615. Acute Myeloid Leukemias: Commercially Available Therapies, Excluding Transplantation and Cellular Immunotherapies: New Approaches to Combination Chemotherapy and Venetoclax Plus Hypomethylating Agent Therapy in AML Research, Acute Myeloid Malignancies, AML, adult, Non-Biological therapies, elderly, Clinical Research, Combination therapy,…
Source: ash.confex.comCategories: Hem/Oncs, Latest HeadlinesTweet-
⚡️limiting VEN exposure to the concurrent days of AZA (7+7 ) had similar response rates like ven for 28d. ⚡️with this 7+7 scheme&ven at 50mg with posa is going to reduce the costs immensely in India with generics for posa and ven😊 https://t.co/UrpsuYU1tC #hemeonc #medtwitter https://t.co/E5aHCBeIR6
-
-
Mashup Score: 0Treatment Options for Paediatric Anaplastic Large Cell Lymphoma (ALCL): Current Standard and beyond - 1 year(s) ago
Anaplastic Lymphoma Kinase (ALK)-positive Anaplastic Large Cell Lymphoma (ALCL), remains one of the most curable cancers in the paediatric setting; multi-agent chemotherapy cures approximately 65–90% of patients. Over the last two decades, major efforts have focused on improving the survival rate by intensification of combination chemotherapy regimens and employing stem cell transplantation for…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet-
management of pediatric Anaplastic Large Cell Lymphoma, one of the most lucid flowchart #alcl #hemeonc #NHL #MedTwitter https://t.co/CX2RytoWLK https://t.co/wzgxDjIqpM
-
-
Mashup Score: 2role of allogeneic transplant for adult Ph+ ALL in CR1 with complete molecular remission: a retrospective analysis - 2 year(s) ago
Key Points. In Ph+ ALL, allogeneic transplant in first remission does not improve survival for patients achieving a deep molecular remission.The use of transpla
Source: American Society of HematologyCategories: Hem/Oncs, Latest HeadlinesTweet-
#leusm #MedTwitter #Practice Changing Updates in Hemat ⚡Ph+ ALL, Allo SCT in CR1 does not improve survival for patients with deep molecular remission ⚡Day 90 Bcr Abl<0.01:no survival benefit with AlloSCT ⚡use of SCT led to ⏬ disease relapse but ⏫ TRM https://t.co/z0T5DYAatX https://t.co/TUQLcBMGqB
-
-
Mashup Score: 36Two-drug versus three-drug induction chemotherapy in pediatric acute myeloid leukemia: a randomized controlled trial - Blood Cancer Journal - 2 year(s) ago
The benefit of three-drug induction chemotherapy over a two-drug induction has not been evaluated in pediatric acute myeloid leukemia (AML). We, therefore, conducted a randomized controlled trial to ascertain the benefit of a three-drug induction regimen. Patients aged 1–18 years with newly diagnosed AML were randomized to two cycles of induction chemotherapy with daunorubicin and ara-C (DA) or…
Source: NatureCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @venkymd: 📖 Our multi-centre study: 2 drug vs 3 drug induction in pediatric acute myeloid leukemia https://t.co/D1Gieq0wVN ✅ No benefit…
-
-
Mashup Score: 0Smm to mgus - 2 year(s) ago
BIOLOGICAL INSIGHTS INTO MGUS AND SMOLDERING MYELOMA
Source: www.slideshare.netCategories: Hem/Oncs, Latest HeadlinesTweet-
Smm to mgus : my very first seminar as a hemato oncology trainee.. #lymsm #mm #myeloma #leusm #mmsm #mgus https://t.co/pQ6sQdxuq5 via @SlideShare
-
-
Mashup Score: 0Instagram - 2 year(s) ago
eha_hematology 308 posts · 2,271 followers
Source: www.instagram.comCategories: Hem/Oncs, Latest HeadlinesTweet-
https://t.co/cGWQMfgYuj
-
RT @TalhaBadarMD: Overlapping features of therapy-related and de novo NPM1-mutated AML https://t.co/DARsu08XzZ➡️ 3 yr OS for t-NPM1 AML, dn…